Could a new combo slash hormone therapy time for prostate cancer?
NCT ID NCT07550517
First seen May 01, 2026 · Last updated May 23, 2026 · Updated 4 times
Summary
This study tests whether adding a targeted radiation drug (177Lu-PSMA-617) to standard radiation allows men with high-risk prostate cancer to take hormone therapy for only 6 months instead of the usual 24 months. The goal is to see if the shorter hormone course is just as effective at controlling cancer while causing fewer side effects. About 60 men will participate, and the study is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK LOCALIZED PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins University
Baltimore, Maryland, 21287, United States
Conditions
Explore the condition pages connected to this study.